Nebivolol

A cardioselective ADRENERGIC BETA-1 RECEPTOR ANTAGONIST (beta-blocker) that functions as a VASODILATOR through the endothelial L-arginine/ NITRIC OXIDE system. It is used to manage HYPERTENSION and chronic HEART FAILURE in elderly patients.

Also Known As:

Networked: 622 relevant articles (142 outcomes, 219 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Giles, Thomas D: 12 articles (06/2017 - 07/2009)
2.	Sowers, James R: 11 articles (09/2012 - 01/2009)
3.	Böhm, Michael: 10 articles (01/2015 - 11/2002)
4.	Coats, Andrew J S: 9 articles (08/2021 - 11/2002)
5.	Fici, Francesco: 9 articles (01/2017 - 08/2005)
6.	van Veldhuisen, Dirk J: 9 articles (10/2012 - 01/2007)
7.	Tavazzi, Luigi: 8 articles (01/2015 - 11/2002)
8.	Flather, Marcus D: 8 articles (08/2014 - 11/2002)
9.	Habibi, Javad: 8 articles (09/2012 - 01/2009)
10.	Roughton, Michael: 7 articles (08/2021 - 06/2009)

Related Diseases

1.	Hypertension (High Blood Pressure) 09/01/2010 - "Nebivolol is effective in mild-to-moderate hypertension and associated with favorable metabolic effects. " 10/01/2004 - "Similarly, the favourable haemodynamic profile of nebivolol, as described by the new investigations (preservation of cardiac output, reduction of peripheral resistance and improved diastolic function) appear to have clinically relevant benefits on the impairment in systolic and/or diastolic function often complicating the hypertension." 01/01/2017 - "Protective effects of nebivolol from oxidative stress to prevent hypertension-related target organ damage." 09/10/2007 - "Protective effects of nebivolol and reversal of endothelial dysfunction in diabetes associated with hypertension." 12/01/2004 - "We found that nebivolol improved left ventricular diastolic function in patients with hypertension in the early term."
2.	Heart Failure 03/01/2006 - "SENIORS study using nebivolol provides best evidence of effective treatment for heart failure in the elderly." 07/01/2006 - "One long-term trial showed a significant reduction in death and hospital admissions for cardiovascular causes when nebivolol was compared with placebo in patients with heart failure (31.1% vs 65.3%; HR 0.86; 95% CI 0.74 to 0.99). " 08/01/2006 - "For example, the vasodilating beta-blocker nebivolol was shown to improve forearm blood flow and arterial stiffness and, in a large clinical study, to significantly reduce morbidity and mortality, independent of left ventricular ejection fraction, among patients with chronic heart failure. " 01/01/2002 - "Treatment with nebivolol was associated with lowering of systolic and diastolic blood pressure (by 22% and 26%, respectively), significant reduction of left ventricular mass index, improvement of parameters of systolic and diastolic left ventricular function and lowering of NYHA class of heart failure. " 01/01/2008 - "The SENIORS trial demonstrated that nebivolol is effective in the treatment of heart failure in elderly patients (e.g. "
3.	Essential Hypertension 11/01/2001 - "Therefore, nebivolol may be recommended as an alternative first-line treatment option for the management of patients with mild to moderate essential hypertension." 01/01/2006 - "Nebivolol should be considered as an alternative first-line treatment option for patients with uncomplicated mild to moderate essential hypertension and in elderly patients with CHF." 03/15/2021 - "Our subanalysis from the real-world BENEFIT-KOREA study in Asian patients with essential hypertension demonstrated the efficacy and safety of once-daily nebivolol across age groups with no between-sex differences. " 03/15/2021 - "BENEFIT-KOREA (BEnefits after 24 weeks of NEbivolol administration For essential hypertensIon patients wiTh various comorbidities and treatment environments in Korea) study, an observational study in South Korea, demonstrated the efficacy and safety of nebivolol in Asian patients with essential hypertension with and without comorbidities in real-world settings. " 01/01/2020 - "Searches of the PubMed, Embase etc. were performed to analyze all the randomized controlled trials using nebivolol to treat essential hypertension. "
4.	Insulin Resistance 03/31/2023 - "Nebivolol Alleviates Vascular Endothelial Insulin Resistance by Inhibiting Endoplasmic Reticulum Stress." 09/01/2021 - "Nebivolol a 3rd generation vasodilatory β-blocker offer neutral or beneficial effects on insulin sensitivity and lipid metabolism. " 12/01/2011 - "Nebivolol improves insulin sensitivity in the TGR(Ren2)27 rat." 01/01/2010 - "In addition, nebivolol does not appear to have adverse effects on lipid metabolism and insulin sensitivity like traditional beta-blockers. " 11/08/2005 - "Data demonstrate that nebivolol administration could participate in the reversion of cardiovascular structural changes associated with the insulin-resistance syndrome."
5.	Reperfusion Injury 01/01/2015 - "The results of this study suggest that nebivolol has protective effects on liver but not on distant organs in a hepatic ischemia/reperfusion injury model. " 11/01/2020 - "Protective effects of nebivolol on ovarian ischemia-reperfusion injury in rat." 01/01/2015 - "These experimental findings indicate that nebivolol may be useful in the treatment of hepatic ischemia/reperfusion injury." 01/01/2021 - "The pretreatment of rats with nebivolol ameliorates bladder contractile dysfunction caused by ischemia-reperfusion injury." 01/01/2015 - "Nebivolol Ameliorates Hepatic Ischemia/Reperfusion Injury on Liver But Not on Distant Organs."

Related Drugs and Biologics

1.	Metoprolol (Toprol-XL)
2.	Antihypertensive Agents (Antihypertensives)
3.	Carvedilol (Coreg)
4.	Bisoprolol (Concor)
5.	Valsartan (Vals)
6.	Nitric Oxide (Nitrogen Monoxide)
7.	Nebivolol
8.	Vasodilator Agents (Vasodilators)
9.	Angiotensin II
10.	Nitric Oxide Synthase (NO Synthase)

Related Therapies and Procedures

1.	Therapeutics
2.	Patient Readmission
3.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
4.	Ligation
5.	Oral Administration